Literature DB >> 16258793

[Prevention of arteriosclerosis. Importance of the treatment of arterial hypertension].

G Bönner1, D B Gysan, G Sauer.   

Abstract

In most European countries and Northern America, cardiovascular diseases induced by atherosclerosis are the most common cause of death in older people. People surviving acute myocardial infarction or stroke suffer often by disabilities or handicaps. The lifelong care of such patients is expensive and plays a major role for increment of costs in public health systems. Prevention of atherosclerosis will reduce cardiovascular morbidity and mortality, enhance quality of life and prolong lifetime of patients. Therefore the worldwide accepted risk factors of atherosclerosis have to be treated consequently and early enough within the meaning of primary prevention. Hypertension is one of the six major cardiovascular risk factors and is defined as elevated blood pressure above 140/90 mmHg. In case of hypertension, diagnostic efforts has to be focussed on detection of additional cardiovascular risk factors, secondary forms of hypertension, end organ damage or associated diseases. All therapeutic strategies are based on life style changes, which cover weight reduction, sodium restriction, controlled alcohol consumption and increment in physical activity. Pharmacotherapy will be added in regard to the global risk of the patient and the success of the life style changes. Selection of antihypertensives and their optimal combination will be determined by associated diseases (compelling indication), side effects and individual response in blood pressure. Goal of treatment is the normalization of blood pressure below 140/90 mmHg independent of age or sex. In diabetics and in case of nephropathy the goal is set lower (below 130/80 mmHg).There is strong evidence that reduction in blood pressure is followed by a decrease in the incidence of myocardial infarction, stroke, heart failure, nephropathy, and even in cardiovascular mortality. The success of antihypertensive therapy is greater in high risk patients like older people, patients with isolated systolic hypertension or diabetics. Risk reduction correlates well with the degree in blood pressure reduction. However, to minimize cardiovascular risk in hypertensives all additional risk factors have to be treated too.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16258793     DOI: 10.1007/s00392-005-1308-9

Source DB:  PubMed          Journal:  Z Kardiol        ISSN: 0300-5860


  44 in total

1.  Monitoring trends and determinants in cardiovascular disease in Germany: results of the MONICA Project Augsburg, 1985-1990.

Authors:  U Keil; B Filipiak; A Döring; H W Hense; M Lewis; H Löwel; J Steiber
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1992-12       Impact factor: 17.586

2.  Shanghai trial of nifedipine in the elderly (STONE).

Authors:  L Gong; W Zhang; Y Zhu; J Zhu; D Kong; V Pagé; P Ghadirian; J LeLorier; P Hamet
Journal:  J Hypertens       Date:  1996-10       Impact factor: 4.844

3.  Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group.

Authors:  L Liu; J G Wang; L Gong; G Liu; J A Staessen
Journal:  J Hypertens       Date:  1998-12       Impact factor: 4.844

4.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Authors:  J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

5.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

6.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

7.  Risk assessment and treatment benefit in intensively treated hypertensive patients of the hypertension Optimal Treatment (HOT) study.

Authors:  A Zanchetti; L Hansson; J Ménard; G Leonetti; K H Rahn; I Warnold; H Wedel
Journal:  J Hypertens       Date:  2001-04       Impact factor: 4.844

8.  The Captopril Prevention Project: a prospective intervention trial of angiotensin converting enzyme inhibition in the treatment of hypertension. The CAPPP Group.

Authors: 
Journal:  J Hypertens       Date:  1990-11       Impact factor: 4.844

9.  Effect of two different therapeutic approaches on total and cardiovascular mortality in a Cardiovascular Study in the Elderly (CASTEL).

Authors:  E Casiglia; P Spolaore; A Mazza; G Ginocchio; G Colangeli; C Onesto; G Di Menza; L Pegoraro; G B Ambrosio
Journal:  Jpn Heart J       Date:  1994-09

10.  The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators.

Authors: 
Journal:  Can J Cardiol       Date:  1996-02       Impact factor: 5.223

View more
  2 in total

1.  Noise perception, heart rate and blood pressure in relation to aircraft noise in the vicinity of the Frankfurt airport.

Authors:  Y Aydin; M Kaltenbach
Journal:  Clin Res Cardiol       Date:  2007-04-10       Impact factor: 5.460

Review 2.  Human cytomegalovirus infection and coronary heart disease: a systematic review.

Authors:  Yu Du; Guangxue Zhang; Zhijun Liu
Journal:  Virol J       Date:  2018-02-06       Impact factor: 4.099

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.